Saltar al contenido
Merck

Loss of the scavenger mRNA decapping enzyme DCPS causes syndromic intellectual disability with neuromuscular defects.

Human molecular genetics (2015-02-26)
Calista K L Ng, Mohammad Shboul, Valerio Taverniti, Carine Bonnard, Hane Lee, Ascia Eskin, Stanley F Nelson, Mohammed Al-Raqad, Samah Altawalbeh, Bertrand Séraphin, Bruno Reversade
RESUMEN

mRNA decay is an essential and active process that allows cells to continuously adapt gene expression to internal and environmental cues. There are two mRNA degradation pathways: 3' to 5' and 5' to 3'. The DCPS protein is the scavenger mRNA decapping enzyme which functions in the last step of the 3' end mRNA decay pathway. We have identified a DCPS pathogenic mutation in a large family with three affected individuals presenting with a novel recessive syndrome consisting of craniofacial anomalies, intellectual disability and neuromuscular defects. Using patient's primary cells, we show that this homozygous splice mutation results in a DCPS loss-of-function allele. Diagnostic biochemical analyses using various m7G cap derivatives as substrates reveal no DCPS enzymatic activity in patient's cells. Our results implicate DCPS and more generally RNA catabolism, as a critical cellular process for neurological development, normal cognition and organismal homeostasis in humans.

MATERIALES
Número de producto
Marca
Descripción del producto

Sigma-Aldrich
DL-Ditiotreitol solution, BioUltra, Molecular Biology, ~1 M in H2O
Supelco
DL-Ditiotreitol solution, 1 M in H2O
Sigma-Aldrich
Cycloheximide, ≥95% (HPLC)
Sigma-Aldrich
Cicloheximida, Biotechnology Performance Certified
Sigma-Aldrich
7-Methylguanosine 5′-diphosphate sodium salt, ≥92.5%
Sigma-Aldrich
Anti-DCPS antibody produced in rabbit, Prestige Antibodies® Powered by Atlas Antibodies, affinity isolated antibody, buffered aqueous glycerol solution